Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P. -L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J. and Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol., 28 (7). S. 1436 - 1448. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Full text not available from this repository.

Abstract

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new basket clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [F-18]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Younes, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hilden, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Coiffier, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hagenbeek, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Salles, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wilson, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seymour, J. F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kelly, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gribben, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfreunschuh, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morschhauser, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoder, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zelenetz, A. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rademaker, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Advani, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Valente, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fortpied, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Witzig, T. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sehn, L. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fisher, R. I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zinzani, P. -L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Federico, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hutchings, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bollard, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trneny, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Elsayed, Y. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tobinai, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Abramson, J. S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fowler, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goy, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Smith, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ansell, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuruvilla, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreyling, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thieblemont, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Little, R. F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aurer, I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Van Oers, M. H. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Takeshita, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gopal, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rule, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Vos, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kloos, I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaminski, M. S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meignan, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwartz, L. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leonard, J. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuster, S. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seshan, V. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-226450
DOI: 10.1093/annonc/mdx097
Journal or Publication Title: Ann. Oncol.
Volume: 28
Number: 7
Page Range: S. 1436 - 1448
Date: 2017
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 1569-8041
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CLASSICAL HODGKINS LYMPHOMA; SINGLE-AGENT LENALIDOMIDE; BONE-MARROW INVOLVEMENT; MANTLE-CELL LYMPHOMA; PHASE-II; FDG-PET/CT; OPEN-LABEL; HARMONIZATION PROJECT; RITUXIMAB MAINTENANCE; FOLLICULAR LYMPHOMAMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/22645

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item